LEF1 targeting EMT in prostate cancer invasion is mediated by miR-181a.
Year: 2015
Type: article
Abstract: Lymphoid enhancer-binding factor-1 (LEF1) is a key transcription factor mediating Wnt signaling pathway. Our previous studies indicate that LEF1 is highly expressed in androgen-independent prostate cancer (PCa) and enhances invasion ability in androgen-independent PCa cells. However, the molecular mechanism of LEF1 effect on invasion remains largely unknown. Using microRNA profiling analysis comparing androgen-independent LNCaP-AI PCa cells with high levels of endogenous LEF1 to LNCaP-AI cells with LEF1 knockdown by LEF1shRNA, we found miR-181a to be increased 12.3-fold in LNCaP-AI cells. We confirmed a positive correlation between LEF1 and miR-181a expression across multiple PCa cell lines. Additionally, we showed that in PCa cells, overexpression of LEF1 increased miR-181a expression and subsequently induced EMT associated migration and invasion, whereas LEF1 knockdown decreased miR-181a expression and subsequently resulted in inhibition of EMT, migration and invasion. Mechanistically, we demonstrated by chromatin immunoprecipitation assays that LEF1 could enhance miR-181a expression via its binding to the promoter regions of hsa-miR-181a. Overall, this study identified a novel LEF1-miR-181a-EMT axis in regulation of PCa migration and invasion.
Source: PubMed
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Awards: Signaling Pathway Alterations in the Racial Disparity of Prostate Cancer, (PQA1) Novel epigenetic mechanism mediate metformin inhibition of prostate cancer, Molecular, Oncology and Immunology Training Grant, Metformin as a novel chemopreventive agent for prostate cancer, Cancer Center Support Grant
OpenAlex ID: W565345012
